Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan to Complete $1 Billion Share Repurchase Plan
Abbott sells remaining 20.3 million shares of Mylan
View HTML
Toggle Summary Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
-- Targeting the initiation of a pivotal patient clinical trial in the first half of 2018 --
View HTML
Toggle Summary Mylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace® Cream
Mylan now offers estradiol in four delivery methodsThe approval showcases Mylan's ongoing investment in complex products
View HTML
Toggle Summary Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH and SAO PAULO , Dec. 29, 2017 /PRNewswire/ -- Biosimilar Trastuzumab, co-developed by Biocon Ltd. (BSE code: 532523, NSE: BIOCON ) and Mylan N.V. (NASDAQ, TASE: MYL), has been approved by ANVISA, the Brazilian regulatory agency, through
View HTML
Toggle Summary Mylan to Present at the 36th Annual J.P. Morgan Healthcare Conference
HERTFORDSHIRE, England and PITTSBURGH , Dec. 20, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced that its CEO, Heather Bresch , will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. , on Tuesday, Jan. 9, 2018 , at 3 p.m. PT ( 6 p.m. ET ).
View HTML
Toggle Summary Mylan to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
HERTFORDSHIRE, England and PITTSBURGH , Dec. 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its CEO, Heather Bresch , will present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top, in Boston, Mass. , on Thursday, Jan. 4, 2018 , at 4 p.m. ET .
View HTML
Toggle Summary Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus® Patents
HERTFORDSHIRE, England and PITTSBURGH , Dec. 14, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings on all claims against two Orange Book-listed patents, U.S. Patent Nos.
View HTML
Toggle Summary Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone® 40 mg/mL
Teva also agrees to withdraw Irish equivalent to U.S. patents from litigation in Ireland
View HTML
Toggle Summary Mylan and Aspen Announce Launch of Generic Busulfex® Injection
HERTFORDSHIRE, England , PITTSBURGH and DURBAN, South Africa , Dec. 4, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) and its partner, Aspen (JSE: APN), today announced the U.S. launch of Myleran (busulfan) Injection, 60 mg/10 mL (6 mg/mL) Single-dose Vial, a generic version of Otsuka
View HTML
Toggle Summary U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers
Mylan anticipates potentially being the first company to provide patient access to a biosimilar to Herceptin®, representing a significant milestone for Mylan, Biocon and the overall healthcare systemThe FDA approval of Ogivri further demonstrates Mylan and Biocon's robust scientific capabilities in developing complex productsOgivri is part of Mylan's robust portfolio of 16 biosimilar and insulin analog products, one of the largest and most diverse
View HTML